U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H27N3O7
Molecular Weight 457.4764
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MINOCYCLINE

SMILES

[H][C@@]12CC3=C(C=CC(O)=C3C(=O)C1=C(O)[C@]4(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]4([H])C2)N(C)C

InChI

InChIKey=DYKFCLLONBREIL-KVUCHLLUSA-N
InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1

HIDE SMILES / InChI
Molecular Formula C23H27N3O7
Molecular Weight 457.4764
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Minocycline is a tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. Minocycline has many brand names one of them is minocin, Minocin is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci etc. Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species etc. MINOCIN also is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection, etc. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Meningitis due to Neisseria meningitidis. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue, etc. Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Minocycline inhibits protein synthesis by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.

CNS Activity

Originator

Approval Year

1971
86
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Curative
Approved
8429
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Curative
Approved
8429
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Curative
Approved
8429
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Curative
Approved
8429
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Primary
Approved
8429
MINOCIN

Approved Use

Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1971
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.63 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050808s014lbl.pdf
135 mg 1 times / day steady-state, oral
dose: 135 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MINOCYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.32 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050808s014lbl.pdf
135 mg 1 times / day steady-state, oral
dose: 135 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MINOCYCLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP450
65
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP450
65
 likely
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:50697
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50697
ChemicalBook
CB6472139
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6472139
MolPort
MolPort-003-666-235
https://www.molport.com/shop/molecule-link/MolPort-003-666-235
eMolecules
2727531
https://www.emolecules.com/cgi-bin/more?vid=2727531
PubMed

PubMed

TitleDatePubMed
Acute hepatic failure associated with oral minocycline: a case report.
1992
Clarithromycin-minocycline is synergistic in a murine model of toxoplasmosis.
1992 Apr
Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways.
2004 Dec
Treatment of olfactory dysfunction, II: studies with minocycline.
2004 Dec
Interstitial pneumonia and hepatitis caused by minocycline.
2004 Feb
Severe acute myopathy induced by minocycline.
2004 Feb 15
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
2004 Jun
The headache of teenage acne.
2004 Jun 8
Drug-induced liver injury.
2004 Mar 1
Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.
2004 Mar 3
Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO.
2004 Mar 3
Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis.
2004 May 25
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria.
2004 May 7
Minocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-cultures.
2004 Nov
An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death.
2004 Nov
A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia.
2004 Oct
Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury.
2004 Oct
Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation.
2004 Oct 5
Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions.
2005
Amyotrophic lateral sclerosis: recent advances and future therapies.
2005 Dec
Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination.
2005 Jan
Case report and review of minocycline-induced cutaneous polyarteritis nodosa.
2005 Jun 15
[Minocycline-induced pleurocarditis and eosinophilic pneumonia: à propos of a case].
2005 Mar
Minocycline in neurological diseases.
2005 Mar
Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage.
2005 May 17
Safety of doxycycline and minocycline: a systematic review.
2005 Sep
Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.
2006
The involvement of norepinephrine and microglia in hypothalamic and splenic IL-1beta responses to stress.
2006 Apr
Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.
2006 Dec 30
Eosinophilic meningitis after implantation of a rifampin and minocycline-impregnated ventriculostomy catheter in a child. Case report.
2006 Jan
Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke.
2006 Jul 17
Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.
2006 May
Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice.
2006 May 8
Additional case of minocycline-induced cutaneous polyarteritis nodosa: comment on the article by Culver et al.
2006 Oct 15
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase.
2007 Apr 15
Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice.
2007 Jan
Minocycline-induced cutaneous polyarteritis nodosa.
2007 Jun
Hyperthyroidism and lupus-like syndrome in an adolescent treated with minocycline for acne vulgaris.
2007 May-Jun
Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia.
2007 Nov
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells.
2007 Nov
Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models.
2007 Nov
Minocycline toxicity requiring liver transplant.
2007 Nov
Pimecrolimus-induced rosacea-like demodicidosis.
2007 Oct
Role of NF-kappaB and MAPKs in light-induced photoreceptor apoptosis.
2007 Oct
Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain.
2007 Oct
[Severe drug rash with eosinophilia and systemic symptoms after treatment with minocycline].
2007 Sep
Minocycline hepatitis.
2008 Aug
Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin.
2008 Aug 8
Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia.
2008 Nov
Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
2009 Feb
Patents

Patents

JP1047747A
12
JP1085953A
3
JP2001335477A
3
JP2001510773A
10
JP2002525268A
31
JP2003519632A
29
JP2003523393A
12
JP2004502752A
12
JP2004505009A
8
JP2004520088A
9
JP2005537097A
12
JP2006503898A
44
JP2006516252A
4
JP2006519264A
58
JP2007502327A
6
JP2007513083A
11
JP2007513165A
55
JP2007532153A
4
JP2009029785A
4
JP2009519341A
24
JP2009526755A
447
JP2010507658A
34
JP2010508915A
8
JP2010540664A
3
JP2011518796A
15
JP2011526302A
67
JP2011527579A
29
JP2011528275A
455
JP2011528367A
4
JP2012500274A
12
JP2012500795A
3
JP2665399B2
7
JP3960481B2
11
JP4213205B2
14
JP4658037B2
37
JP4763957B2
87
JP4787165B2
101
JP4829785B2
3
JP4832641B2
16
JPH01197431A
3
JPH01305030A
3
JPH02138244A
3
JPH02193959A
3
JPH02212418A
3
JPH0276844A
3
JPH03130074A
3
JPH04234313A
14
JPH04321630A
3
JPH069407A
3
JPH0782153A
13
JPH08217679A
12

Sample Use Guides

In Vivo Use Guide
For Pediatric Patients above 8 years of Age: usual pediatric dose: Initial dose of 4 mg/kg, then 2 mg/kg administered over 60 minutes every 12 hours, not to exceed the usual adult dose. Adults: usual adult dose: Initial dose of 200 mg, then 100 mg administered over 60 minutes ever y 12 hours and should not exceed 400 mg in 24 hours.
Route of Administration: Intravenous
In Vitro Use Guide
It was investigated the minimal inhibitory concentration (MIC) of minocycline on superinfecting microorganisms isolated from the periodontal pocket and the oral cavity of individuals with chronic periodontitis. Isolates of Enterobacteriaceae (n = 25), Staphylococcus spp. (n = 25), Pseudomonas aeruginosa (n = 9) and Candida spp. (n = 25) were included in the study. Minimal inhibitory concentrations (MIC) of minocycline were determined using the Müeller-Hinton agar dilution method. Staphylococcus spp. isolates were the most sensitive to minocycline with a MIC of 8 microg/mL, followed by Enterobacteriaceae with a MIC of 16 microg/mL. The concentration of 16 microg/mL inhibited 96% of Candida spp. isolates. The MIC for 88.8% of the isolates of Pseudomonas aeruginosa was 128 microg/mL. A concentration of 1,000 microg/mL was not enough to inhibit 100% of the tested isolates.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:36:02 GMT 2023
Edited
by admin
on Fri Dec 15 15:36:02 GMT 2023
Record UNII
FYY3R43WGO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MINOCYCLINE
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
MINOCYCLINE [USAN]
Common Name English
MINOCYCLINE [MI]
Common Name English
MINOCYCLINE [HSDB]
Common Name English
MINOCYCLINE [MART.]
Common Name English
minocycline [INN]
Common Name English
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
Common Name English
MINOCYCLINE [VANDF]
Common Name English
2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S-(4.ALPHA.,4A.ALPHA.,5A.ALPHA.,12A.ALPHA.))-
Common Name English
Minocycline [WHO-DD]
Common Name English
TIGECYCLINE IMPURITY C [EP IMPURITY]
Common Name English
Classification Tree Code System Code
WHO-VATC QA01AB23
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
LIVERTOX NBK547956
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
NDF-RT N0000007948
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
WHO-VATC QJ01AA08
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
NDF-RT N0000007948
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
WHO-ATC A01AB23
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
NCI_THESAURUS C1595
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
NDF-RT N0000175882
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
WHO-ATC J01AA08
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
Code System Code Type Description
CAS
10118-90-8
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
ChEMBL
CHEMBL1434
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
DAILYMED
FYY3R43WGO
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
HSDB
3130
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID1045033
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
CHEBI
50694
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
MERCK INDEX
m7553
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
PRIMARY Merck Index
FDA UNII
FYY3R43WGO
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
LACTMED
Minocycline
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
RXCUI
6980
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C61849
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
PRIMARY
EVMPD
SUB08980MIG
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
DRUG BANK
DB01017
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
CHEBI
77906
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
WIKIPEDIA
MINOCYCLINE
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
PRIMARY
MESH
D008911
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
PRIMARY
DRUG CENTRAL
1813
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
SMS_ID
100000091981
Created by admin on Fri Dec 15 15:36:03 GMT 2023 , Edited by admin on Fri Dec 15 15:36:03 GMT 2023
PRIMARY
INN
1646
Created by admin on Fri Dec 15 15:36:02 GMT 2023 , Edited by admin on Fri Dec 15 15:36:02 GMT 2023
PRIMARY
Related Record Type Details
Structure of MINOCYCLINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of MINOCYCLINE HYDROCHLORIDE DIHYDRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 9-HYDROXYMINOCYCLINE
METABOLITE -> PARENT
URINE
Structure of N7-DEMETHYLMINOCYCLINE
METABOLITE -> PARENT
URINE
Structure of N4-DEMETHYLMINOCYCLINE
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of TIGECYCLINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of MINOCYCLINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: HAEMOPHILUS INFLUENZAE

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: HAEMOPHILUS INFLUENZAE

Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL PATHOGEN: STREPTOCOCCUS PNEUMONIAE

SUSCEPTIBILITY: SUSCEPTIBLE

MIC BIOLOGICAL PATHOGEN: ENTEROBACTERIACEAE, ACINETOBACTER, STAPHYLOCOCCUS AUREUS, VIBRIO CHOLERATE

SUSCEPTIBILITY: INTERMEDIATE

Biological Half-life PHARMACOKINETIC POPULATION: HEPATIC IMPAIRMENT

ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL PATHOGEN: STREPTOCOCCUS PNEUMONIAE

SUSCEPTIBILITY: RESISTANT

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: HAEMOPHILUS INFLUENZAE

MIC BIOLOGICAL PATHOGEN: STREPTOCOCCUS PNEUMONIAE

SUSCEPTIBILITY: INTERMEDIATE

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

Tmax PHARMACOKINETIC ROUTE OF ADMINISTRATION: EXTENDED RELEASE TABLET

Tmax PHARMACOKINETIC DOSAGE FORM: CAPSULE, PELLET FILLED

Tmax PHARMACOKINETIC DOSAGE FORM: TABLET

Biological Half-life PHARMACOKINETIC With renal impairment
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC POPULATION: RENAL IMPAIRMENT

ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ENTEROBACTERIACEAE, ACINETOBACTER, STAPHYLOCOCCUS AUREUS, VIBRIO CHOLERATE

ORAL BIOAVAILABILITY PHARMACOKINETIC
MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: ENTEROBACTERIACEAE, ACINETOBACTER, STAPHYLOCOCCUS AUREUS, VIBRIO CHOLERATE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966